Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435680 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02435680 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT02435680, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
Interventions
- DRUG carboplatin
- DRUG gemcitabine
- DRUG MCS110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435680
The ClinicalTrials.gov registry entry for NCT02435680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT02435680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435680 about?
NCT02435680 is a clinical study titled "Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)". To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
What is the current status of trial NCT02435680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-08-10. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02435680?
The interventions under investigation include: carboplatin (DRUG), gemcitabine (DRUG), MCS110 (DRUG).
Who is sponsoring clinical trial NCT02435680?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.